II. Changes of the registration dossier for a registered medicinal product that require expert examination of proposed methods of quality control of the medicinal product and quality of submitted samples of the drug product using and (or) expert examination of the expected benefit to the possible risk ratio of the medicinal product use
|
|
N
n/a
|
Type (nature) of changes
|
Sections of the registration dossier for a medicinal product containing the documents to be modified
|
Examination of the proposed methods of quality control of the medicinal product and the quality of submitted samples of the medicinal product using these methods
|
Examination of the ratio of the expected benefit to the possible risk of use of the medicinal product
|
|
Evaluation of documents and information submitted by the applicant
|
Examination of the quality of drug product samples
|
|
1.
|
Change of the trade name of a medicinal product
|
Administrative documentation
|
-
|
-
|
+
|
|
2.
|
Change of the INN or grouping name or chemical name of a medicinal product
|
Administrative documentation
|
+
|
-
|
+
|
|
3.
|
Change of the name of the API (international nonproprietary name, or grouping name, or chemical and trade name)
|
Administrative documentation
|
+
|
-
|
-
|
|
4.
|
Changes related to modifications in the name or code of the medicinal product according to the anatomical-therapeutic-chemical (ATC) classification recommended by the World Health Organization
|
Administrative documentation
|
-
|
-
|
+
|
|
5.
|
Change of the dosage form of the medicinal product without change of qualitative and (or) quantitative composition of active ingredients and (or) qualitative composition of excipients of the medicinal product
|
Administrative documentation
|
+
|
-
|
+
|
|
6.
|
Change in the description of the finished dosage form caused by addition, change or removal of engravings, thickenings or other markings that do not affect the dosing of the medicinal product, as well as change in the form of tablets, capsules, suppositories
|
Administrative documentation;
Chemical, pharmaceutical and biological documentation
|
+
|
-
|
+
|
|
7.
|
Changes in information on pharmacodynamics and pharmacokinetics of the medicinal product
(excluding pharmacokinetics of homeopathic and herbal drug products)
|
Administrative documentation;
Pharmacological, toxicological, clinical documentation
|
-
|
-
|
+
|
|
8.
|
Change and (or) addition of indications for use of the medicinal product
|
Administrative documentation;
Pharmacological, toxicological, clinical documentation
|
-
|
-
|
+
|
|
9.
|
Change and (or) addition of contraindications for use of the medicinal product
|
Administrative documentation
Pharmacological, toxicological, clinical documentation
|
-
|
-
|
+
|
|
10.
|
Change and/or adding new precautions for use of the medicinal product
|
Administrative documentation
Pharmacological, toxicological, clinical documentation
|
-
|
-
|
+
|
|
11.
|
Change of instructions on the possibility of use and special warnings for use of the medicinal product in pregnant and/or breastfeeding women, children and adults with chronic diseases
|
Administrative documentation
Pharmacological, toxicological, clinical documentation
|
-
|
-
|
+
|
|
12.
|
Change in dosing regimen, routes of administration and posology, administration
timing, treatment duration, including for children under and after one year of age
|
Administrative documentation
Pharmacological, toxicological, clinical documentation
|
-
|
-
|
+
|
|
13.
|
Change and (or) addition of the information on possible side effects and adverse reactions when using the medicinal product
|
Administrative documentation;
Pharmacological, toxicological, clinical documentation
|
|
|
+
|
|
14.
|
Change of the information on symptoms of the overdose, measures to treat overdosing
|
Administrative documentation;
Pharmacological, toxicological, clinical documentation
|
-
|
-
|
+
|
|
15.
|
Change of the information on interaction with other medicinal products and (or) food
|
Administrative documentation;
Pharmacological, toxicological, clinical documentation
|
-
|
-
|
+
|
|
16.
|
Change of the release forms of the medicinal product
|
Administrative documentation;
Pharmacological, toxicological, clinical documentation
|
+
|
-
|
+
|
|
17.
|
Adding or replacing of a measuring device for dosage forms
|
Administrative documentation;
Chemical, pharmaceutical and biological documentation
|
+
|
+
(if the change is likely to have significant impact on quality, efficiency and safety of the drug product)
|
+
|
|
18.
|
Change of the features of the effects on the first take or after stop taking the medicinal product
|
Administrative documentation;
Pharmacological, toxicological, clinical documentation
|
-
|
-
|
+
|
|
19.
|
Changes of the information about the possible effects of the medicinal product on the ability to drive vehicles and operate mechanisms
|
Administrative documentation;
Pharmacological, toxicological, clinical documentation
|
-
|
-
|
+
|
|
20.
|
Change of the shelf life of the medicinal product
|
Administrative documentation;
Chemical, pharmaceutical and biological documentation
|
+
|
-
|
-
|
|
21.
|
Change of the storage conditions of medicinal drugs
(i.e. either API or drug product)
|
Administrative documentation;
Chemical, pharmaceutical and biological documentation
|
+
|
-
|
-
|
|
22.
|
Change of the dispensing conditions for the medicinal product
|
Administrative documentation
|
-
|
-
|
+
|
|
23.
|
Changing and/or adding quality control parameters, quality control methods and/or adding of alternative quality control method
(i.e. either API or drug product)
|
Administrative documentation;
Chemical, pharmaceutical and biological documentation
|
+
|
+
(with respect to changed or added parameters of quality and corresponding analytical methods)
|
-
|
|
24.
|
Removal of quality control parameters, quality control methods and/or deletion of an alternative quality control method
(i.e. either API or drug product)
|
Administrative documentation;
Chemical, pharmaceutical and biological documentation
|
+
|
-
|
-
|
|
25.
|
Changes to bring the normative documentation of the medicinal drug in compliance with the requirements of the State Pharmacopoeia
|
Administrative documentation;
Chemical, pharmaceutical and biological documentation
|
+
|
+
(in the case of changes of the analytical methods or addition of new quality parameters)
|
|
|
26.
|
Removal of a dosage of the medicinal product
|
Administrative documentation
|
+
|
-
|
+
|
|
27.
|
Changes to the Risk Management Plan for a biologic drug product
|
Administrative documentation
|
-
|
-
|
+
|
|
28.
|
Change or addition of one or more participants in the manufacturing process of the medicinal product associated with the change in the place of manufacturing of the medicinal product
|
Administrative documentation;
Chemical, pharmaceutical and biological documentation
|
+
|
+
(except for secondary packaging and releasing quality control sites)
(for sites, where manufacturing operations are performed for biological, immunological medicinal products or medicinal products anufctured by complex manufacturing processes, according to the tests specified by the request of the expert institutions (if available)
|
+
|
|
29.
|
Change of the manufacturing process and (or) manufacturing technology and (or) change of QC methods at one or several stages of production of a medicinal drug
(i.e. either API or the drug product)
|
Chemical, pharmaceutical and biological documentation
|
+
|
-
(in case of absence of changes in the specification of the medicinal drug)
|
+
only for biological drug products
|
|
30.
|
Change in the manufacturing process of herbal medicinal product relating to change in the geographic source, method of production or manufacture of the herbal medicinal product
|
Chemical, pharmaceutical and biological documentation
|
+
|
+
|
+
|
|
31.
|
Changes in the specification of the API
|
Chemical, pharmaceutical and biological documentation
|
+
|
+
only for biological drug products
|
+
only for biological drug products
|
|
32.
|
Change in the quality control methods used in the quality control of medicinal drugs
(i.e. either API or drug product)
|
Administrative documentation;
Chemical, pharmaceutical and biological documentation
|
+
|
+
|
-
|
|
33.
|
Change of the characteristics and properties of packaging materials and closure system of the API primary packaging
|
Chemical, pharmaceutical and biological documentation
|
+
|
-
|
-
|
|
34.
|
Change in the stability data on the medicinal drug
(i.e. either API or drug product)
|
Chemical, pharmaceutical and biological documentation
|
+
|
-
|
-
|
|
35.
|
Change in the shelf life of the API
|
Chemical, pharmaceutical and biological documentation
|
+
|
-
|
-
|
|
36.
|
Change in the description and (or) composition of excipients included to the medicinal product
|
Administrative documentation;
Chemical, pharmaceutical and biological documentation
|
+
|
+
(except for changes of references to specifications of excipients, included to the composition of the medicinal product)
|
+
|
|
37.
|
Changes in the microbiological characteristics of the drug product
|
Chemical, pharmaceutical and biological documentation
|
+
|
+
|
-
|
|
38.
|
Change of the primary packaging of medicinal products in terms of inclusion of additional packaging or replacement of primary packaging
|
Administrative documentation;
Chemical, pharmaceutical and biological documentation
|
+
|
+
(if the change of primary packaging can render substantial impact on quality, efficiency and safety of medicinal drug)
|
+
|
|
39.
|
Changes in toxicological properties data of the medicinal product
|
Pharmacological, toxicological, clinical documentation
|
-
|
-
|
+
|
|
40.
|
Changes in data on bioavailability and bioequivalence of the medicinal product
|
Clinical documentation
|
-
|
-
|
+
|
|
41.
|
Changes in data on clinical efficacy and safety of the medicinal product
|
Pharmacological, toxicological, clinical documentation
|
-
|
-
|
+
|
|
42.
|
Change of data on post-registration study(es) experience of the medicinal product
|
Clinical documentation
|
-
|
-
|
+
|